Compare ARK Genomic Revolution ETF (ARKG) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Snap On Incorporated — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Snap On Incorporated trades at $401.94 (market cap $20.82B). The key difference: Snap On Incorporated pays a 2.43% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | SNA | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $413.62 |
52-Week Low | $23.09 | $313.01 |
Market Cap | — | $20.82B |
Enterprise Value | — | $20.34B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Snap-on Incorporated (SNA) trades at $401.94, up 0.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $407.50. The company reported strong profitability with a 19.6% net income margin and a 17.83% ROE for 2025. Recent strategic acquisitions, including Diesel Laptops for $100 million, aim to expand its heavy-duty diagnostics capabilities, while a $500 million share repurchase authorization and consistent dividends underscore shareholder returns.
The outlook is positive, supported by operational agility and steady cash flow growth, with net cash flow rising to $318 million projected for 2026. Key risks include muted revenue growth and margin pressures, as seen in the Q1 2026 earnings miss. Investor sentiment is cautiously optimistic, with 65% of analysts rating the stock a buy, but competitive and macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
